PBYI
Puma Biotechnology Inc

6,863
Mkt Cap
$290M
Volume
1.05M
52W High
$7.68
52W Low
$2.58
PE Ratio
7.70
PBYI Fundamentals
Price
$6.42
Prev Close
$5.70
Open
$5.51
50D MA
$6.44
Beta
0.85
Avg. Volume
408,164.65
EPS (Annual)
$0.6142
P/B
2.49
Rev/Employee
$1.28M
$230.31
Loading...
Loading...
News
all
press releases
Puma Biotechnology (NASDAQ:PBYI) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded Puma Biotechnology from a "buy" rating to a "hold" rating in a research note on Saturday...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View
Puma Biotechnology Q4 earnings top estimates with 28% revenue jump, but weak 2026 outlook sparks 14% after-hours plunge.
Zacks·3d ago
News Placeholder
Puma Biotechnology Q4 Earnings Call Highlights
Puma Biotechnology (NASDAQ:PBYI) reported fourth-quarter 2025 total revenue of $75.5 million, driven by NERLYNX product revenue and a sharp increase in royalty revenue, according to management's...
MarketBeat·4d ago
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Announces Earnings Results
Puma Biotechnology (NASDAQ:PBYI - Get Free Report) issued its earnings results on Thursday. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, topping the...
MarketBeat·4d ago
News Placeholder
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates
Puma Biotech (PBYI) delivered earnings and revenue surprises of +20.83% and +11.26%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are...
Business Wire·4d ago
News Placeholder
Jazz Pharmaceuticals (JAZZ) Beats Q4 Earnings and Revenue Estimates
Jazz (JAZZ) delivered earnings and revenue surprises of +0.27% and +1.56%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
Puma Biotechnology to Present at TD Cowens 46th Annual Health Care Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at...
Business Wire·7d ago
News Placeholder
Puma Biotechnology (PBYI) to Release Earnings on Thursday
Puma Biotechnology (NASDAQ:PBYI) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...
MarketBeat·12d ago
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Share Price Passes Above Two Hundred Day Moving Average - Should You Sell?
Puma Biotechnology (NASDAQ:PBYI) Shares Cross Above Two Hundred Day Moving Average - What's Next...
MarketBeat·13d ago
<
1
2
...
>

Latest PBYI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.